<DOC>
	<DOCNO>NCT00940953</DOCNO>
	<brief_summary>The primary objective study compare Placebo Captisol-Enabled Budesonide + Azelastine single spray two separate spray ( Budesonide + Azelastine ) patient Seasonal Allergic Rhinitis expose control ragweed pollen .</brief_summary>
	<brief_title>Compare Captisol-Enabled ( CE ) Budesonide + Azelastine Nasal Solution Rhinocort Aqua + Astelin Environmental Exposure Chamber ( EEC ) Study Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>Patients must clinical history SAR Adults ( male female ) age 18 65 Patients must documentation positive skin test within 12 month screen ragweed allergen define positive case history positive skin prick and/or intradermal test ragweed allergen . Nonpregnant , nonlactating female , woman postmenopausal naturally surgically sterile Females childbearing potential must confirm absence pregnancy accord negative urine pregnancy test must use acceptable birth control method In generally good health basis medical history physical examination . Willingness attend study visit . Capable follow understanding instruction . Willing able provide write informed consent prior initiation study procedure , include initiation washout concomitant medication Pregnancy , nursing , plan become pregnant donate gamete ( ova sperm ) invitro fertilization Have clinically significant physical finding nasal anatomical deformity cause great 50 % obstruction base clinical estimate investigator , include nasal polyp , septal defect clinically significant respiratory tract malformation , recent nasal biopsy , nasal trauma , surgery atrophic rhinitis rhinitis medicamentosa Previous participation budesonide study within 1 month prior Screening Visit . Currently participate clinical trial expose investigational treatment within 30 day prior Screening Visit . A known hypersensitivity corticosteroid excipients formulation investigational drug ( e.g. , adverse experience budesonide , azelastine Captisolcontaining product Vfend IV Geodon IM ) . History severe respiratory infection disorder History alcohol drug abuse History positive test HIV , hepatitis B hepatitis C. Use prohibit medication within identify exclusion period Use antibiotic therapy acute condition Initiation immunotherapy dose escalation study period . Nonvaccinated exposure active infection chickenpox measles within 21 day precede Screening Visit . Exposure systemic corticosteroid Use topical corticosteroid concentration excess 1 % hydrocortisone equivalent History epilepsy seizures History coronary heart disease , uncontrolled hypertension , clinically significant cardiovascular disease . Have follow condition judge investigator clinically significant and/or affect patient 's ability participate clinical trial : Impaired hepatic function include alcohol relate liver disease cirrhosis History ocular disturbance ( e.g. , glaucoma posterior subcapsular cataract ) Any systemic infection Hematological , renal , endocrine ( except control diabetes mellitis postmenopausal symptom hypothyroidism ) Gastrointestinal disease Malignancy ( exclude basal cell carcinoma ) A current neuropsychiatric condition without drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>